Personalised Medicine in 2012: Editorial to the Special Issue of new biotechnology on "molecular diagnostics & personalised medicine"

New Biotechnology

Volumn 29, Issue 6, 2012, Pages 611-612

  Desiere, Frank ^a   Romano Spica, Vincenzo ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; ECONOMICS; EDITORIAL; GENOMICS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; IMMUNOLOGY; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; REIMBURSEMENT;

HUMANS; INDIVIDUALIZED MEDICINE; INVENTIONS; PATHOLOGY, MOLECULAR;

EID: 84865434941     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.03.010     Document Type: Editorial

References (7)

1. Editorial Nat. Biotechnol. 2012, 30:1.
2. Orphan Drug Act, Public Law 97-414, January 4, 1983, as amended.
3. Sheridan C. Pfizer swallows Wyeth, validates niche buster. Nat. Biotechnol. 2009, 27:218-219.
4. Hunt V., et al. A wake-up call for Big Pharma Lower profit margins suggest a need for new business models. McKinsey Q. 2011.
5. Flaherty K.T., et al. Vemurafenib. Nat. Rev. Drug Discov. 2011, 10:811-812. 10.1038/nrd3579.
6. Shaw A.T., et al. Crizotinib. Nat. Rev. Drug Discov. 2011, 10:897-898. 10.1038/nrd3600.
7. Pollack A. A push to tie new drugs to testing. New York Times 2011, 26:2011.